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ABSTRACT 
BACKGROUND 
Non-epithelial neoplasm involving the breast 
is uncommon. Hodgkin's lymphoma in rare 
cases present primarily as localised extra-
nodal involvement of the breast. This report 
aims to present a case of Hodgkin's lymphoma 
of the breast treated by chemotherapy with 
complete remission achieved. 
METHOD 
The case records of a 66 years old female who 
presented with a six-month history of swelling 
in left armpit and a left breast mass of 4 
months duration and a literature review of the 
subject utilizing existing literature, Medline 
and google search were utilized. 
RESULT 
A tissue diagnosis of Hodgkin's lymphoma 
with typical Reed-Sternberg cells seen after 
incisional biopsy. The use of 
cyclophosphamide, vincristine, procarbazine 
and prednisolone for chemotherapy achieved 
complete remission. 
CONCLUSION 
Hodgkin's lymphoma should be considered as 
a differential for mitotic lesion of the breast as 
the prognosis is favourable and treatment 
excludes mastectomy with its morbidity and 
psychosocial considerations. 
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INTRODUCTION 
Adenocarcinomas are usually the most 
common malignant breast tumor. 1 Non-
epithelial neoplasm involving the breast is 
uncommon, as only 0.1% ofbreast cancers are 
from extra-nodal lymphoma.2' 3 Malignant 
lymphoma involving the breast may be 
primary and localised with or without regional 
lymphadenopathy, or part of a disseminated 
spread. Diffuse large B cell lymphoma (Non-
Hodgkin's lymphoma) is the most common 
subtype of malignant lymphoma encountered 
in several series.4' 5 
Lymphoma rarely involves the breast as a 
primary lesion in the absence of a previously 
detected lymphoma localizations. 6 However 
when it does it is usually of B-cell origin and 
rarely from T-cell with a common denominator 
being the presence of Hodgkin Reed-
Sternberg cells HRS. 7 
With advances in genetic molecular and 
immunological biotechniques, five subtypes of 
Hodgkins lymphoma have been identified as 
presented in the WHO classification. 8 
Classical Hodgkin's lymphoma bear CD30 
antigen while nodular lymphocyte 
predominant Hodgkin's lymphoma carry the 
CD20 antigen. 9 These CD antigen can be 
targeted in relapse after treatment with 
Rituximab or Brentixumab, chimeric 
monoclonal antibody against the CD 20 and 
CD30 proteins respectively. 
Hodgkin's lymphoma is a highly curable 
malignancy. It was the first cancer to be cured 
with radiation therapy alone or with a 
combination of several chemotherapeutic 
agents even before the understanding of its 
biology improved. 
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Advances in treatment of Hodgkin's Her anaemia was corrected with blood 
lymphoma have led to cure in 90% of all transfusions and sequential combined 
diagnosed patients.10 chemotherapy commenced. This comprised 
We report this rare case to remind clinicians 
that Hodgkin's lymphoma is a differential 
diagnosis ofbreast masses and to highlight its 
favourable prognosis. 
CASE REPORT 
A 66-year-old woman presented to the surgical 
clinic with a 6-month history of progressive 
swelling in the left axilla. The lump was 
associated with a dull continuous pain. 
Incidentally, she received Hepatitis B vaccine 
at the left upper arm two days before onset of 
symptoms. 
Two months later a lump was noticed in the 
left breast. The lump rapidly increased in size 
with associated dull pain and soon ulcerated. 
There was some weight loss but no jaundice, 
ascites or bone pain. 
A physical examination revealed an elderly 
woman with facial asymmetry- deviation of 
the mouth to the left (presumably from Bell's 
palsy). The left breast was enlarged with 
peaud' orange and a tender fungating firm 
oval mass 8x10cm in size. There were some 
firm, tender matted lymph nodes involving the 
medial and posterior groups of the left axilla. 
There was also supraclavicular and 
infraclavicular lymphadenopathy. The liver 
was enlarged, extending Scm below the costal 
margin. 
Her packed cell volume (PCV) was 25% while 
the erythrocyte sedimentation rate was 
120mmlhr. She tested positive to HIV 1&11 
but Hepatitis B Surface antigen and Hepatitis 
C antibody were negative. 
Incisional biopsy of the lump demonstrated 
typical Reed-Sternberg cells on histology, 
confirming the diagnosis of Hodgkin's 
lymphoma. Her liver and renal function tests 
revealed no abnormality although abdominal 
ultrasonography showed enlarged liver. The 
chest radiograph was also normal. 
four 28-day cycles of intravenous 
cyclophosphamide 500mg/m2 days1&8, 
intravenous vincristine 2mg days 1& 8, 
procarbazine tablets 600mg days 1 to14 and 
Prednisolone tablets 40mg days 1 
to14.Remission of tumour was achieved 
following this regimen(Figures 1,2 and 
3).There was non-availability of Positron 
Emission Tomography PET scan to assess 
completeness of remission. However the 
reduction in breast tissue remained after 12 
months of follow-up. 
Figure 1: Patient at presentation 
Figure 2: Patient after 2nd courses of 
chemotherapy 
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Figure 3: Patient after 4 courses of sedimentation rate, liver and renal functional 
chemotherapy tests. Others include HIV screening, chest 
DISCUSSION 
There is paucity of reports on Hodgkin's 
disease (HD) in African literature with that of 
the breast being even worse. The median ages 
reported for primary extra-nodal breast 
lymphoma are between 40 and 67 years.9 
According to the WHO classification, there are 
five subtypes of Hodgkin's disease namely; 
lymphocyte predominant, nodular sclerosis, 
mixed cellularity, lymphocyte depletion and 
nodular lymphocyte predominant. 
Mixed cellularity and lymphocyte depleted 
subtypes of HD are more common in the 
developing countries probably due to its 
association with Human Immunodeficiency 
virus.lt is noteworthy that the index patient is 
retroviral positive 
The aetiology of HD like most malignancies is 
unknown; however, infectious agents, genetic 
and environmental factors are implicated. The 
infectious agents include Epstein Barr virus, 
Hepatitis B and C, Human T-lymphocytic 
Type-1 virus and Human immunodeficiency 
virus. In the index case vaccination with 
Hepatitis B vaccine (live vaccine) preceded the 
lymphoma. 
The stage of the disease is one of the most 
important prognostic factors. Staging of the 
disease requires history and physical 
examination, full blood count, erythrocyte 
radiograph, abdominal ultrasound and CT 
scan. Positron Emission 1bmography PET is 
now considered essential where available 
because it is useful in the evaluation of 
response to chemotherapy and even predictive 
of survival. n -l" 
Bilateral bone marrow biopsies are advised 
due to patchy marrow involvement, while a 
histological diagnosis of Reed Sternberg cells 
is pathognomonic. 
Lymphoma may present in the breast as part 
of a widespread disease or after 
radiotherapy/treatment for a primary nodal or 
extra-nodal lymphoma. The criteria for 
diagnosis of primary breast lymphoma include 
breast tissue and lymphomatous infiltrates in 
close association, in the absence of concurrent 
widespread disease. 16 
Hodgkin's disease is a curable malignancy but 
its treatment can have serious long term 
complications. The challenges of advances in 
treatment protocols are twofold: to minimize 
the treatment given to patients with early 
stage, low risk disease and to safely minimize 
the treatment given to patients with disease 
that is likely to be refractory to standard 
therapies. There has been a shift in recent 
times from radiation therapy alone to 
chemoradiotherapy. Chemotherapeutic 
regimens include MOPP, ABVD, BEACOPP, 
Stanford V and COPP. The latter was used in 
the index case. The choice of this regimen was 
based on availability with the advantage of 
eliminating the complication of pulmonary 
fibrosis associated with bleomycin containing 
regimens. Radiation therapy is administered 
to the involved field or regional field to 
incorporate adjacent lymph nodes to a dose of 
about 30Gy. The goal of therapy is complete 
remission with disappearance of all evidence 
of the disease. It is gratifying to observe there 
was complete remission of disease without 
radiotherapy in this patient. 
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Despite a high cure rate relapse may occur. In 6. Joks M, Mysliwiec K, Lewandoswski K. 
such cases salvage chemotherapy, monoclonal Primary breast lymphoma-a review of the 
antibodies against CD-30 (SGN -35), high dose literature and report of three cases .. Arch 
chemotherapy with bone marrow MedSci2011;7, 1:27-33 
transplantation are options to be considered.16' 7. Kuppers R, Rajewsky K, Zhao M,Simons 
17 An adequate follow up is therefore G,Laumann R,Fischer R,Hansmann ML. 
imperative. Hodgkin disease: Hodgkin and Reed-
Surgery in its modification is an age old 
modality of treatment for breast cancer. 
Following surgery are significant morbidities 
including nerve injury, inadvertent 
pneumothorax and serious psychosocial 
problems. In malignant lymphoma of the 
breast, mastectomy is rarely a treatment 
option. 
CONCLUSION 
Primary breast lymphoma is a rare, more so, 
Hodgkin's lymphoma of the breast. 
Chemotherapy alone or chemotherapy with 
radiotherapy can achieve remission. This 
favourable treatment outcome without the 
morbidity of radical surgery underscores the 
importance of accurate tissue diagnosis before 
mastectomy. 
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